Diabetes mellitus, antidiabetics and bone
Authors:
Štěpán Svačina
Authors‘ workplace:
Univerzita Karlova v Praze, 1. lékařská fakulta, III. interní klinika VFN
Published in:
Čas. Lék. čes. 2010; 149: 282-284
Category:
Review Article
Overview
A short review of current opinions on a questionable and controversial disease – diabetic osteopathy – is presented. Bone metabolism is influenced by antidiabetic drugs. Positive effects are attributed to the insulin and metformin therapy. Use of thiazolidindiones is accompanied by a higher risk of bone fractures in diabetic women. Very interesting and also promising is the effect of glucagon like peptide-1 and the new antidiabetic drug class- incretin analogues on bone metabolism.
Key words:
diabetic osteopathy, thiazolidindiones, glucagon like peptid-1, incretin analogues.
Sources
1. Fisman EZ, Tenenbaum A. (eds.) Cardivascular diabetology. Advances in kardiology vo. 45. Basel: Karger 2008.
2. Pickup JC, Williams G. (eds.) Textbook of diabetes. Blackwell 2004; kap. 61.10.
3. Adami S. Bone health in diabetes: considerations for clinical management. Curr Med Res Opin 2009; 25(5): 1057–1072.
4. Strotmeyer ES, et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 2005; 165(14): 1612–1617.
5. Strotmeyer ES, et al. Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: The Health, Aging, and Body Composition Study. J Bone Miner Res 2004; 19(7): 1084–1091.
6. Fantuzzi G, Mazzone Th. (eds.) Adipose tissue in health and disease. Totowa: Humana Press 2007.
7. Palička V. Léky ovlivňující kostní metabolismus u diabetiků. Vnitr Lek 2009; 55(4): 368–370.
8. Gao Y, Li Y, Xue J, Jia Y, Hu J. Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats. Eur J Pharmacol 2010; 19. E-pub.
9. Kahn SE, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008; 31(5): 845–851.
10. Zinman B, et al: Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab 2010; 95(1): 134–142.
11. Douglas IJ, Evans SJ, Pocock S, Smeeth L. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med 2009; 6(9): e1000154.
12. Meier C, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168(8): 820–825.
13. Jones SG, Momin SR, Good MW, Shea TK, Patric K. Distal upper and lower limb fractures associated with thiazolidinedione use. Am J Manag Care 2009; 15(8): 491–496.
14. Haluzík M, Svačina Š. Inkretinová léčba diabetu. Praha: Mladá fronta 2010.
15. Bjerre Knudsen L, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151(4): 1473–1486.
16. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide – the FDA‘s review of a new antidiabetic therapy. N Engl J Med 2010; 362(9): 774–777.
17. Yamada C, et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 2008; 149(2): 574–579.
18. Borm AK. The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus. Horm Metab Res 1999; 31(8): 472–475.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
Most read in this issue
- Acoustic neuroma – vestibular schwannoma – personal experience of up-to-date management
- Calcitonin and his role in regulation of calcium-phosphate metabolism
- Beta-blockers in flow of time – view of an anaesthesiologist and intensivist
- Type 2 diabetes mellitus as a subclinical inflammation